Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
07:30am, Monday, 28'th Apr 2025
– Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure –
Kura Oncology to Report First Quarter 2025 Financial Results
07:30am, Thursday, 24'th Apr 2025
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicin
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
07:30am, Tuesday, 08'th Apr 2025
– Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation – – Submission seeks approval for the treatment of adult patients with relaps
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 04'th Apr 2025
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicin
Kura Oncology to Participate in Stifel Targeted Oncology Forum
07:30am, Tuesday, 01'st Apr 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
07:30am, Wednesday, 26'th Mar 2025
– Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-28
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 07'th Mar 2025
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicin
Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity
10:12am, Tuesday, 04'th Mar 2025
Kura Oncology's ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax's revumenib. Kura's strong cash position supports operations throu
Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript
04:46am, Thursday, 27'th Feb 2025
Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Patti Bank - IR Troy Wilson - President and CEO Mollie Leoni - CMO Tom Doyle - SVP
Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates
06:35pm, Wednesday, 26'th Feb 2025
Kura Oncology (KURA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.55 per share a year ago.
Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results
04:03pm, Wednesday, 26'th Feb 2025
– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR
Kura Oncology to Participate in Three Upcoming Investor Conferences
07:30am, Tuesday, 25'th Feb 2025
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine
Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results
07:30am, Wednesday, 19'th Feb 2025
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 07'th Feb 2025
SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
12:05pm, Thursday, 06'th Feb 2025
Kura Oncology, Inc. KURA and Kyowa Kirin Co., Ltd released topline results from a Phase 2 registration-directed trial of ziftomenib for relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid le
